HOME >> MEDICINE >> NEWS
New class of drugs may treat lung tumors resistant to Iressa and Tarceva

A new class of drugs that block the epidermal growth factor receptor (EGFR) on lung cancer cells may get around the growing problem of resistance to targeted therapy drugs like Iressa and Tarceva. In a report to appear in Proceedings of the National Academy of Science, researchers from Massachusetts General Hospital (MGH) Cancer Center and colleagues from Wyeth Pharmaceuticals research division describe finding how drugs called irreversible EGFR inhibitors apparently avoid resistance and may offer patients longer term remission. The study has received early online release on the PNAS website.

"These irreversible inhibitors form an unbreakable bond with the EGFR molecule," says Daniel Haber, MD, PhD, director of the MGH Cancer Center and senior author of the PNAS paper. "The initial group of EGFR inhibitors can fall off the receptor, but once the irreversible inhibitors bind, the receptor is permanently out of commission." The researchers also discovered a new mechanism underlying the development of resistance, one which the new drugs may be able to avoid.

EGFR inhibitors, like Iressa (gefitinib) and Tarceva (erlotinib), are used to treat advanced non-small-cell lung cancer (NSCLC), the leading cause of cancer deaths in the U.S. In 2004 MGH researchers found that a particular set of mutations in the EGFR molecule could identify patients whose tumors would respond to Iressa, which early clinical trials indicated was effective in less than 15 percent of patients. The identified mutations magnified the cells' response to growth factor, fueling tumor growth, but they also increased tumors' sensitivity to Iressa. Subsequent research found that similar mutations were associated with sensitivity to Tarceva.

Although results for those patients who did respond to these EGFR inhibitors were often rapid and dramatic, they were also short lived, lasting for an average of 6 to 8 months. Researchers at several centers attributed this resistance
'"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
16-May-2005


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. Early-morning Friday classes may prevent students from getting sloppy on thirsty Thursdays
3. Panel offers guidelines on skin reactions to new class of cancer drugs
4. UK researchers find new class of nontoxic cancer treatments
5. New class of HIV drug attacks previously untargeted enzyme
6. New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer
7. Sleep disturbances affect classroom performance
8. Simple classification can help define and predict limb-threatening diabetic infections
9. World-class Biomedical Research Center to be in West London
10. A new way of classifying addictive drugs
11. Phys ed class more effective when theres more talking

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2019)... ... ... TIME For Kids (TFK) revealed the first-ever list of the ... destinations that are tailored to the interests of kids. The list identifies The Children’s ... list, TIME for Kids gathered nominations from its network of TFK Kid Reporters ...
(Date:12/5/2019)... ... December 05, 2019 , ... Abide, the #1 Christian meditation and sleep ... year using Bible-based bedtime stories. Listeners have recovered from bad dreams and night terrors, ... for Disease Control, one third of Americans suffer from poor sleep, which is linked ...
(Date:12/5/2019)... ... December 05, 2019 , ... It’s been an impactful year ... help people embrace, achieve, and maintain a healthy lifestyle to giving generously to ... our mission of impacting world health, so it’s gratifying to look back on ...
(Date:12/4/2019)... ... December 04, 2019 , ... ... Extract®, provides protection from disruptions to cells and tissue and inflammation that leads ... Jet Lag, is available in a dietary supplement product called Prepair™ . ...
(Date:12/4/2019)... ... 2019 , ... While the holidays are a time for joy and sharing, ... AgriLife Extension Service specialists. , “There are many behavioral and logistical ... wellness,” said Joyce Cavanagh, AgriLife Extension specialist in family economics, College Station. , Prioritize ...
Breaking Medicine News(10 mins):
(Date:12/5/2019)... ... December 05, 2019 , ... nView, a leading behavioral ... the role of Chief Product Officer. As the company expands its portfolio of ... the behavioral health market into nView’s product and company growth strategy. Rosenbaum will ...
(Date:12/4/2019)... ... December 04, 2019 , ... Tenex ... minimally invasive technologies to treat chronic pain in soft and hard tissue, recently ... TX® technology. , Dr. Bernard Morrey, Chief Medical Officer of Tenex ...
(Date:12/4/2019)... ... December 04, 2019 , ... HGE Health, ... COPD patient’s symptoms, joined forces nearly a year ago with RespirCare, an operator ... care at times when the attention is most needed. The patient-satisfaction scores ...
Breaking Medicine Technology:
Cached News: